Key result
Combined aspirin and clopidogrel therapy significantly reduced the vein graft occlusion rate compared to aspirin alone (7.4% vs 13.1%; p=0.04) following off-pump coronary artery bypass surgery.
Why the study?
Does aspirin plus clopidogrel improve graft patency and platelet inhibition compared to aspirin alone in patients following off-pump coronary artery bypass surgery?
RCT (n=300)
computer-generated algorithm
No
Does aspirin plus clopidogrel improve graft patency and platelet inhibition compared to aspirin alone in patients following off-pump coronary artery bypass surgery?
Dual antiplatelet therapy with aspirin and clopidogrel significantly reduces vein graft occlusion rates at 12 months following off-pump CABG compared to aspirin alone.
Supports dual antiplatelet therapy after off-pump CABG; extends randomized evidence on graft patency.
OBJECTIVE: To determine the individual variability in the response to aspirin and/or clopidogrel and its impact on graft patency after off-pump coronary artery bypass grafting. DESIGN: A single-centre prospective randomised controlled study designed according to the Consolidated Standards of Reporting Trials statement. Randomisation was obtained by a computer-generated algorithm. SETTING: University medical school in Italy. PATIENTS: 300 patients who underwent off-pump coronary artery bypass grafting were randomised to receive aspirin (n=150) or aspirin plus clopidogrel (n=150). INTERVENTION: Aspirin 100 mg or aspirin 100 mg plus clopidogrel 75 mg daily was initiated when postoperative chest tube drainage was ≤ 50 ml/h for 2 h and patients were followed up for 12 months. MAIN OUTCOME MEASURES: Qualitative and quantitative assessment of platelet function, angiographic evaluation of coronary revascularisation by 64-slice CT and clinical outcome. RESULTS: In the aspirin group, 49 patients (32.6%) were aspirin resistant and, in the aspirin-clopidogrel group, 19 patients (12.6%) were aspirin and clopidogrel resistant. The platelet response to aspirin was similar in all aspirin responders despite the study arm (Aspirin Reaction Units 313.2 ± 44.8 vs 323.6 ± 53.6; p=0.07). The platelet response to clopidogrel was enhanced by aspirin in patients responsive to both aspirin and clopidogrel (synergistic effect) compared with responders to clopidogrel only (P2Y12 Reaction Units 139.9 ± 15.5 vs 179.4 ± 18.5; p<0.001). Combined therapy was associated with a reduced vein graft occlusion rate (7.4% vs 13.1%; p=0.04). Antiplatelet resistance was a predictor of graft occlusion (RR 3.6, 95% CI 2.5 to 6.9; p<0.001). Synergistic aspirin and clopidogrel activity was a strong predictor of vein graft patency (RR 5.1, 95% CI 1.4 to 16.3; p<0.01). CONCLUSIONS: Combined clopidogrel and aspirin overcome single drug resistances, are safe for bleeding and improve venous graft patency.
No takes yet. Share an insight, caveat, or question.
Mannacio et al. (2012) conducted an RCT in off-pump coronary artery bypass grafting (n=300). aspirin plus clopidogrel vs. aspirin 100 mg daily was evaluated on vein graft occlusion rate (p=0.04). Combined aspirin and clopidogrel therapy significantly reduced the vein graft occlusion rate compared to aspirin alone (7.4% vs 13.1%; p=0.04) following off-pump coronary artery bypass surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: